{{Rsnum
|rsid=2494732
|Gene=AKT1
|Chromosome=14
|position=104772855
|Orientation=plus
|GMAF=0.4472
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=AKT1
}}[[rs2494732]] is a SNP in the [[AKT1]] gene, encoding one of three serine/threonine-protein kinases regulating numerous processes such as cell survival, growth and angiogenesis. Medical conditions that may be linked to the rarer (minor) [[rs2494732]](C) allele include drug response, [[schizophrenia]], and drug-related psychoses, in particuler, [[cannabis]]-related psychosis.

{{PMID|22831980}} A case-control study of 489 first-episode psychosis patients concluded that while [[rs2494732]] was not associated with an increased risk of a psychotic disorder, with lifetime cannabis use, or with frequency of use, there was a significant association between psychosis and cannabis use. [[rs2494732]](C;C) individuals with a history of cannabis use had an increased likelihood of a psychotic disorder (odds ratio 2.18, CI: 1.1 - 4.3) when compared with users who were (T;T) carriers. The interaction between the rs2494732 genotype and frequency of use was also somewhat significant (likelihood ratio = 13.39; p = .010). Among daily users, (C;C) carriers had a 7x increase in the odds of psychosis compared with (T;T) carriers (odds ratio 7.23, CI: 1.37 - 38.12).

{{PMID|18855532}} among (likely Japanese) 120 first-episode neuroleptic-naive schizophrenics treated with [[risperidone]] genotyped for 30 variants in misc. dopamine and serotonin (receptors and otherwise) two SNPs in DRD2 ([[rs1799989]] and [[rs1800497]]) and two SNPs in AKT1 ([[rs3803300]] and [[rs2494732]]) were significant predictors of treatment response to risperidone

The ancestral allele is C in the [http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs2494732 dbSNP] database.

{{PharmGKB
|RSID=rs2494732
|Name_s=
|Gene_s=AKT1
|Feature=
|Evidence=PubMed ID:18855532
|Annotation=This SNP is significant predictor of treatment response to risperidone in first-episode schizophrenia.
|Drugs=risperidone
|Drug Classes=
|Diseases=Schizophrenia
|Curation Level=Curated
|PharmGKB Accession ID=PA162356249
}}

{{PMID Auto
|PMID=22277669
|Title=Genetic overlap between schizophrenia and bipolar disorder: A study with AKT1 gene variants and clinical phenotypes
}}

{{PMID Auto
|PMID=16260726
|Title=Detection of functional single-nucleotide polymorphisms that affect apoptosis.
|OA=1
}}

{{PMID Auto
|PMID=16395129
|Title=Absence of significant associations between four AKT1 SNP markers and schizophrenia in the Taiwanese population.
}}

{{PMID Auto
|PMID=17464696
|Title=AKT1 and neurocognition in schizophrenia.
}}

{{PMID Auto
|PMID=18497887
|Title=Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans.
|OA=1
}}

{{PMID Auto
|PMID=18715757
|Title=Genetic associations with schizophrenia: meta-analyses of 12 candidate genes.
|OA=1
}}

{{PMID Auto
|PMID=19051289
|Title=Association of AKT1 with verbal learning, verbal memory, and regional cortical gray matter density in twins.
|OA=1
}}

{{PMID Auto
|PMID=19461960
|Title=Absence of AKT1 mutations in glioblastoma.
|OA=1
}}

{{PMID Auto
|PMID=19931325
|Title=No association between AKT1 polymorphism and schizophrenia: a case-control study in a Korean population and a meta-analysis.
}}

{{PMID Auto
|PMID=20046382
|Title=AKT1 Gene Polymorphisms and Obstetric Complications in the Patients with Schizophrenia.
|OA=1
}}

{{PMID Auto
|PMID=21041608
|Title=Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: sibling analysis and proband follow-up.
}}

{{PMID Auto
|PMID=21775978
|Title=AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder.
|OA=1
}}

{{PMID Auto
|PMID=21842521
|Title=AKT1 polymorphisms and survival of early stage non-small cell lung cancer.
}}

{{PMID Auto
|PMID=22150081
|Title=The AKT1 gene is associated with attention and brain morphology in schizophrenia.
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2494732
|overall_frequency_n=4904
|overall_frequency_d=10754
|overall_frequency=0.456016
|n_genomes=42
|n_genomes_annotated=0
|n_haplomes=57
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23747160
|Title=No association between AKT1 gene variants and schizophrenia: a Malaysian case-control study and meta-analysis
}}

{{PMID Auto
|PMID=25060489
|Title=Genetic variants in AKT1 gene were associated with risk and survival of OSCC in Chinese Han Population
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}